Cologne, October 14, 2014 – New Oncology announced today that it has entered into a collaboration agreement with Institute Gustave Roussy, Paris. Under this agreement, New Oncology will perform comprehensive parallel multigene testing to identify therapeutically relevant alterations in cancer-related genes. New Oncology will apply its proprietary diagnostic platform ‘NEO’, which allows rapid sample processing compatible with both daily clinical routine and standard sample material, i.e. FFPE (formalin-fixed, paraffin-embedded) tissue. No financial details were disclosed.
“We are very pleased to partner with Gustave Roussy, Europe’s leading oncology centers. We look forward to contributing New Oncology’s unique diagnostic platform enabling in-depth genetic profiling of tumor samples. Together, we expect to significantly improve personalized approaches for the benefit of cancer patients” commented Dr. Andreas Jenne, CEO of New Oncology.
“The dramatic responses seen in patients receiving targeted treatment have shifted the therapeutic paradigm to therapies which are based on the molecular characteristics of a given cancer. Thus, comprehensive genomic diagnosis of FFPE tissues is an important step to optimize clinical care to patients throughout the different lines of therapy” said Professor Jean Charles Soria, Head of the Drug Development Department at Gustave Roussy Cancer Campus.
About New Oncology
New Oncology’s proprietary diagnostic platform ‘NEO’ empowers physicians to select the optimal targeted therapy for their patients, including participation in suitable clinical trials. Our pan-cancer diagnostic test NEOplus reliably detects actionable genetic alterations with short turn-around times. In contrast to conventional testing, NEOplus identifies all types of therapeutically relevant alterations, i.e. mutations, amplifications, insertions/deletions, as well as novel and known translocations, from one single patient sample. We work with a tumor board comprising renowned cancer experts, facilitating translation of the latest findings in targeted therapy into optimized patient care.
About Institute Gustave Roussy
Europe’s leading oncology center, Gustave Roussy is an international institute whose expertise in oncology is entirely dedicated to its patients. At the institute, 2,600 health professionals are dedicated to the three main missions of care giving, research, and education. By devoting 20% of its budget to research, Gustave Roussy proudly signals its determination to promote research as an innovative engine for the benefit of its patients. Gustave Roussy is a private health facility working within the French public health system and is authorized to receive donations and bequests.
NEO New Oncology AG